Journals / Retina-Vitreus / 2019 / Cilt: 28 - Sayı: 1

Results of Topical Brinzolamide Treatment in Patients Diagnosed X-linked Retinischisis

X’e Bağlı Juvenil Retinoskizisde Topikal Brinzolamid Tedavisi Sonuçlarımız

Pages
32–36
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In patients with XLRS, topical brinzolamide administration may provide some improvement in visual acuity and relative stabi- lization in central macular thickness.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the result of topical brinzolamide treatment in patients diagnosed with X-linked juvenile retinoschisis (XLRS).
📊
Key Findings & Data:Subjects and Methods: Files of 16 patients with XLRS diagnosed between January 2010 and January 2016 were reviewed retrospectively and 16 eyes of 8 patients who were on topical brinzolamide treatment for at least 12 months or more were included into the study.
💡
Conclusion & Impact:Conclusion: In patients with XLRS, topical brinzolamide administration may provide some improvement in visual acuity and relative stabi- lization in central macular thickness.
🔬Design:Review & Systematic Survey
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the result of topical brinzolamide treatment in patients diagnosed with X-linked juvenile retinoschisis (XLRS). Subjects and Methods: Files of 16 patients with XLRS diagnosed between January 2010 and January 2016 were reviewed retrospectively and 16 eyes of 8 patients who were on topical brinzolamide treatment for at least 12 months or more were included into the study. Changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated. Results: Mean age of the subjects was 12.8±4.2 years (Range: 6-18 years) and the mean follow-up time was 36.0±24.0 months (Range: 12-84 months). Median BCVA with Snellen chart was 0.2 (Range: 0.1-0.6) and mean CMT was 509.3±124.7 micron (Range: 215-646 micron) at the baseline. Topical brinzolamide was prescribed as tid in all patients. Median BCVA was 0.25 (Range: 0.1-0.7) and mean CMT was 457.8±135.6 micron (Range: 202-714 micron)) at the last visit. There was a statistical difference in baseline and fi nal BCVA and CMT (p<0.05). The BCVA improved more than one line in 9 eyes, unchanged in six eyes and was worsened more than one line in one eye despite the decrease of CMT. A reduction of at least 20% in CMT were achieved in 4 eyes, 10-20% in 4 eyes, under 10% in 5 eyes at the end of follow-up. Increase of CMT was observed in 3 eyes despite the topical brizolamide treatment. Conclusion: In patients with XLRS, topical brinzolamide administration may provide some improvement in visual acuity and relative stabi- lization in central macular thickness.

Özet

Amaç: X’e bağlı juvenil retinoskizis tanılı hastalarda topikal brinzolamid tedavisi sonuçlarını değerlendirmek. Materyal - Metod: Ocak 2010- Ocak 2016 tarihleri arasında X’e bağlı juvenil retinoskizis tanısı konulan 16 hastanın dosyaları geriye dönük olarak incelendi. Topikal brinzolamid tedavisi başlanan, 12 ay ve üzeri takibi olan 8 hastanın 16 gözü çalışmaya dahil edilerek en iyi düzeltilmiş görme keskinliği (EİDGK) ve santral maküler kalınlıklarındaki (SMK) değişiklikler değerlendirildi. Bulgular: Ortalama yaş 12.8±4.2 yıl (6-18 yıl) ve ortalama takip süresi 36.0±24.0 ay (12-84 ay) olarak bulundu. İlk muayenedeki ortanca EİDGK Snellen eşeli ile 0.2 (Aralık: 0.1-0.6) iken ortalama SMK 509.3±124.7 mikron (Aralık: 215-646 mikron) olarak ölçüldü. Hastalara brizolamid damla günde 3x1 olarak reçete edildi. Son muayenedeki ortanca EİDGK 0.25 (Aralık: 0.1-0.7) iken ortalama SMK 457.8±135.6 mikron (Aralık: 202-714 mikron) olarak ölçüldü. İlk ve son muayenedeki EİDGK ve SMK arasında istatistiksel olarak anlamlı fark mevcuttu (p<0.05). Dokuz gözde Snellen eşelinde en az 1 sıra ve üzeri artış olurken, 6 gözde görme keskinliği aynı seviyedeydi. Sadece bir gözde SMK azalmasına rağmen görme keskinliğinde azalma olduğu saptandı. Takiplerde 4 gözde %20 ve üzeri, 4 gözde %10-20 arası, 5 gözde %10 altı SMK’da düşme saptandı. Üç gözde ise tedaviye rağmen SMK’da kalınlaşma olduğu görüldü. Sonuç: X’e bağlı maküler retinoskizisli hastalarda topikal brinzolamid ile hem görme keskinliğinde kazanım, hem de optik koherens tomog- rafi de görece stabilizasyon sağlanabilmektedir.

🔖

Cite This Article

KARATAŞ, E., AYHAN, Z., YAMAN, A., SAATÇİ, A. O. (2019). Results of Topical Brinzolamide Treatment in Patients Diagnosed X-linked Retinischisis. Retina-Vitreus, Cilt: 28 - Sayı: 1, 32–36. https://ajindex.com/articles/304803

References (11)

  1. Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschi- sis: clinical diagnosis, genetic analysis, and molecular mecha- nisms. Prog Retin Eye Res. 2012;31(3):195-212.
  2. Hull S, Arno G, Sergouniotis PI, Tiffi n P, Borman AD, Chandra A, et al. Clinical and molecular characterization of enhanced S-cone syndrome in children. JAMA ophthalmology. 2014;132(11):1341- 9. Tantri A, Vrabec TR, Cu-Unjieng A, Frost A, Annesley WH, Jr., Donoso LA. X-linked retinoschisis: a clinical and molecular genetic review. Surv ophthalmol. 2004;49(2):214-30.
  3. Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007;44(4):225-32.
  4. Prenner JL, Capone A, Jr., Ciaccia S, Takada Y, Sieving PA, Trese MT. Congenital X-linked retinoschisis classifi cation system. Retina. 2006;26(7):S61-4. Dadacı Z AN, Borazan M. X’e bağlı juvenil retinoskizis: bir olgu sunumu ve tanı ve tedavideki güncel yaklaşımların değerlendirilmesi. Retina-Vitreus. 2016;24(1):83-5 Molday RS. Focus on molecules: retinoschisin (RS1). Exp Eye Res. 2007;84(2):227-8.
  5. Kim DY, Mukai S. X-linked juvenile retinoschisis (XLRS): a review of genotype-phenotype relationships. Semin Ophthalmol. 2013;28(5-6):392-6.
  6. Fahim AT, Ali N, Blachley T, Michaelides M. Peripheral fundus fi ndings in X-linked retinoschisis. Br J of Ophthalmol. 2017;101(11):1555-9.
  7. Aydın E KL, Özçift SG. Juvenil retinoskizisli iki olguda fundus fl urosein angiografi ve spektral domain optik koherens tomografi bulgularının değerlendirilmesi. Retina-Vitreus. 2015;23(1):80-4
  8. Gregori NZ, Berrocal AM, Gregori G, Murray TG, Knighton RW, Flynn HW, Jr., et al. Macular spectral-domain optical coherence tomography in patients with X-linked retinoschisis. Br J Ophthalmol. 2009;93(3):373-8.
  9. Stringa F, Tsamis E, Papayannis A, Chwiejczak K, Jalil A, Biswas S, et al. Segmented swept source optical coherence tomography angiography assessment of the perifoveal vasculature in patients with X-linked juvenile retinoschisis: a serial case report. Int Med Case Rep J. 2017;10:329-35.
  10. Yu H, Li T, Luo Y, Yu S, Li S, Lei L, et al. Long-term outcomes of vitrectomy for progressive X-linked retinoschisis. Am J Ohthalmol. 2012;154(2):394-402. Verbakel SK, van de Ven JP, Le Blanc LM, Groenewoud JM, de Jong EK, Klevering BJ, et al. Carbonic anhydrase inhibitors for the treatment of cystic macular lesions in children with x-linked juvenile retinoschisis. Invest Ophthalmol Vis Sci. 2016;57(13):5143-7.
  11. Salvatore S, Fishman GA, Genead MA. Treatment